Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 263

1.

Intelligent liver function testing (iLFT): A trial of automated diagnosis and staging of liver disease in primary care.

Dillon JF, Miller MH, Robinson EM, Hapca A, Rezaeihemami M, Weatherburn C, McIntyre PG, Bartlett B, Donnan PT, Boyd KA, Dow E.

J Hepatol. 2019 Oct;71(4):699-706. doi: 10.1016/j.jhep.2019.05.033. Epub 2019 Jun 19.

PMID:
31226388
2.

Frontline Science: RIP2 promotes house dust mite-induced allergic airway inflammation.

Miller MH, Shehat MG, Alcedo KP, Spinel LP, Soulakova J, Tigno-Aranjuez JT.

J Leukoc Biol. 2018 Sep;104(3):447-459. doi: 10.1002/JLB.4HI0118-017RR. Epub 2018 Jul 27.

3.

Development and validation of diagnostic triage criteria for liver disease from a minimum data set enabling the 'intelligent LFT' pathway for the automated assessment of deranged liver enzymes.

Miller MH, Fraser A, Leggett G, MacGilchrist A, Gibson G, Orr J, Forrest EH, Dow E, Bartlett W, Weatherburn C, Laurell A, Grant K, Scott K, Neville R, Dillon JF.

Frontline Gastroenterol. 2018 Jul;9(3):175-182. doi: 10.1136/flgastro-2017-100909. Epub 2018 Feb 7.

4.

Correction to: Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease.

Spanos C, Maldonado EM, Fisher CP, Leenutaphong P, Oviedo-Orta E, Windridge D, Salguero FJ, Bermúdez-Fajardo A, Weeks ME, Evans C, Corfe BM, Rabbani N, Thornalley PJ, Miller MH, Wang H, Dillon JF, Quaglia A, Dhawan A, Fitzpatrick E, Moore JB.

Proteome Sci. 2018 Jun 25;16:13. doi: 10.1186/s12953-018-0142-8. eCollection 2018.

5.

Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease.

Spanos C, Maldonado EM, Fisher CP, Leenutaphong P, Oviedo-Orta E, Windridge D, Salguero FJ, Bermúdez-Fajardo A, Weeks ME, Evans C, Corfe BM, Rabbani N, Thornalley PJ, Miller MH, Wang H, Dillon JF, Quaglia A, Dhawan A, Fitzpatrick E, Moore JB.

Proteome Sci. 2018 Feb 14;16:4. doi: 10.1186/s12953-018-0131-y. eCollection 2018. Erratum in: Proteome Sci. 2018 Jun 25;16:13. Bernadette Moore, J [corrected to Moore, J Bernadette].

6.

Genetic Factors Influencing Drug-Induced Liver Injury: Do They Have a Role in Prevention and Diagnosis?

Clare KE, Miller MH, Dillon JF.

Curr Hepatol Rep. 2017;16(3):258-264. doi: 10.1007/s11901-017-0363-9. Epub 2017 Aug 7. Review.

7.

Editorial: sorafenib toxicity, a biomarker of effect?

Clare KE, Miller MH, Dillon JF.

Aliment Pharmacol Ther. 2017 Jun;45(11):1469-1470. doi: 10.1111/apt.14033. No abstract available.

8.

Gamma glutamyl transferase 'To be or not to be' a liver function test?

Dillon JF, Miller MH.

Ann Clin Biochem. 2016 Nov;53(6):629-631. doi: 10.1177/0004563216659887. Epub 2016 Jul 20. No abstract available.

PMID:
27384446
9.

Early diagnosis improves outcomes in hepatitis C.

Miller MH, Dillon JF.

Practitioner. 2015 Nov;259(1787):25-7, 3. Review.

PMID:
26753270
10.

Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease.

Wood KL, Miller MH, Dillon JF.

BMJ Open Gastroenterol. 2015 Feb 17;2(1):e000019. doi: 10.1136/bmjgast-2014-000019. eCollection 2015.

11.

Complications and outcomes of phacoemulsification cataract surgery complicated by anterior capsule tear.

Carifi G, Miller MH, Pitsas C, Zygoura V, Deshmukh RR, Kopsachilis N, Maurino V.

Am J Ophthalmol. 2015 Mar;159(3):463-9. doi: 10.1016/j.ajo.2014.11.027. Epub 2014 Nov 26.

PMID:
25461300
12.

Update on the treatment of hepatitis C genotypes 2-6.

Paterson JC, Miller MH, Dillon JF.

Curr Opin Infect Dis. 2014 Dec;27(6):540-4. doi: 10.1097/QCO.0000000000000114. Review.

PMID:
25313502
13.

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease.

Bradford V, Dillon J, Miller M.

Hepat Med. 2013 Dec 11;6:1-10. doi: 10.2147/HMER.S34472. eCollection 2014. Review.

14.

Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy.

Miller MH, Agarwal K, Austin A, Brown A, Barclay ST, Dundas P, Dusheiko GM, Foster GR, Fox R, Hayes PC, Leen C, Millson C, Ryder SD, Tait J, Ustianowski A, Dillon JF; British Viral Hepatitis group; British Society of Gastroenterology Liver Committee; British Association for the Study of Liver; Scottish Society of Gastroenterology; Scottish Viral Hepatitis group; Scottish Viral Hepatitis Nurses group.

Aliment Pharmacol Ther. 2014 Jun;39(12):1363-75. doi: 10.1111/apt.12764. Epub 2014 Apr 22.

15.

Serum proteome of nonalcoholic fatty liver disease: a multimodal approach to discovery of biomarkers of nonalcoholic steatohepatitis.

Miller MH, Walsh SV, Atrih A, Huang JT, Ferguson MA, Dillon JF.

J Gastroenterol Hepatol. 2014 Oct;29(10):1839-47. doi: 10.1111/jgh.12614.

PMID:
24750217
16.

Commentary: real-world triple therapy experience treating hepatitis C virus.

Heron T, Miller MH, Dillon JF.

Aliment Pharmacol Ther. 2014 Mar;39(5):542. doi: 10.1111/apt.12599. No abstract available.

17.

Effective Advocacy in Rural Domains: Applying an Ecological Model to Understanding Advocates' Relationships.

Johnson M, McGrath SA, Miller MH.

J Interpers Violence. 2014 Aug;29(12):2192-2217. Epub 2014 Jan 23.

PMID:
24457219
18.

Oesophageal bacterial biofilm changes in gastro-oesophageal reflux disease, Barrett's and oesophageal carcinoma: association or causality?

Blackett KL, Siddhi SS, Cleary S, Steed H, Miller MH, Macfarlane S, Macfarlane GT, Dillon JF.

Aliment Pharmacol Ther. 2013 Jun;37(11):1084-92. doi: 10.1111/apt.12317. Epub 2013 Apr 22.

19.

Commentary: assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers.

Miller MH, Dillon JF.

Aliment Pharmacol Ther. 2013 Jan;37(2):275. doi: 10.1111/apt.12134. No abstract available.

20.

Spontaneous bacterial peritonitis prophylaxis in the era of healthcare associated infection.

Jafferbhoy HM, Miller MH, Gashau W, Chandrashekar C, Henry EB, Lockhart M, Dillon JF.

Gut. 2012 Nov;61(11):1644-5. Epub 2012 Mar 22. No abstract available.

PMID:
22442163
21.

Intravenous drug use: not a barrier to achieving a sustained virological response in HCV infection.

Jafferbhoy H, Miller MH, Dunbar JK, Tait J, McLeod S, Dillon JF.

J Viral Hepat. 2012 Feb;19(2):112-9. doi: 10.1111/j.1365-2893.2011.01446.x. Epub 2011 May 9.

PMID:
22239500
22.

Bacterial translocation in cirrhosis is not caused by an abnormal small bowel gut microbiota.

Steed H, Macfarlane GT, Blackett KL, Macfarlane S, Miller MH, Bahrami B, Dillon JF.

FEMS Immunol Med Microbiol. 2011 Dec;63(3):346-54. doi: 10.1111/j.1574-695X.2011.00857.x. Epub 2011 Sep 8.

23.

The effectiveness of outreach testing for hepatitis C in an immigrant Pakistani population.

Jafferbhoy H, Miller MH, McIntyre P, Dillon JF.

Epidemiol Infect. 2012 Jun;140(6):1048-53. doi: 10.1017/S095026881100152X. Epub 2011 Aug 19.

PMID:
21854668
24.

Pre-treatment prediction of response to pegylated-interferon plus ribavarin for chronic hepatitis C using RVR.

Jafferbhoy H, Miller MH, El Wahed Z, Dillon JF.

J Hepatol. 2011 Nov;55(5):1162-4; author reply 1164-6. doi: 10.1016/j.jhep.2011.04.005. Epub 2011 May 10. No abstract available.

25.

Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease.

Miller MH, Ferguson MA, Dillon JF.

Liver Int. 2011 Apr;31(4):461-73. doi: 10.1111/j.1478-3231.2011.02451.x. Epub 2011 Feb 1. Review.

PMID:
21382157
26.

Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens.

Pillai R, Deeter R, Rigl CT, Nystrom JS, Miller MH, Buturovic L, Henner WD.

J Mol Diagn. 2011 Jan;13(1):48-56. doi: 10.1016/j.jmoldx.2010.11.001. Epub 2010 Dec 23.

27.

YAG laser peripheral iridotomy for the prevention of pigment dispersion glaucoma a prospective, randomized, controlled trial.

Scott A, Kotecha A, Bunce C, Balidis M, Garway-Heath DF, Miller MH, Wormald R.

Ophthalmology. 2011 Mar;118(3):468-73. doi: 10.1016/j.ophtha.2010.07.026. Epub 2010 Oct 29.

PMID:
21035866
28.

Binaphthyl-based dicationic peptoids with therapeutic potential.

Bremner JB, Keller PA, Pyne SG, Boyle TP, Brkic Z, David DM, Garas A, Morgan J, Robertson M, Somphol K, Miller MH, Howe AS, Ambrose P, Bhavnani S, Fritsche TR, Biedenbach DJ, Jones RN, Buckheit RW Jr, Watson KM, Baylis D, Coates JA, Deadman J, Jeevarajah D, McCracken A, Rhodes DI.

Angew Chem Int Ed Engl. 2010;49(3):537-40. doi: 10.1002/anie.200904392. No abstract available.

PMID:
20014083
29.

Genetics and deafness: implications for education and life care of deaf students.

Schein JD, Miller MH.

Am Ann Deaf. 2008 Fall;153(4):408-10.

PMID:
19146077
30.

How to eliminate air-bone gaps audiometrically: use too much masking.

Miller MH.

Ear Nose Throat J. 2008 May;87(5):273-6.

PMID:
18572783
31.

Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate.

Buchbinder R, Barber M, Heuzenroeder L, Wluka AE, Giles G, Hall S, Harkness A, Lewis D, Littlejohn G, Miller MH, Ryan PF, Jolley D.

Arthritis Rheum. 2008 Jun 15;59(6):794-9. doi: 10.1002/art.23716.

32.

Ménière's disease.

Miller MH.

J Am Acad Audiol. 2006 Jan;17(1):4-5. No abstract available.

PMID:
16640055
33.

Selected complex auditory disorders.

Miller MH, Schein JD.

J Rehabil Res Dev. 2005 Jul-Aug;42(4 Suppl 2):1-8. Review.

34.

Teamwork between otologists and audiologists.

Miller MH.

Ear Nose Throat J. 2005 Dec;84(12):804; author reply 804. No abstract available.

PMID:
16408565
35.

Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae.

Jumbe NL, Louie A, Miller MH, Liu W, Deziel MR, Tam VH, Bachhawat R, Drusano GL.

Antimicrob Agents Chemother. 2006 Jan;50(1):310-7.

36.

Making sense of OSHA's final rule.

Miller MH, Crane MA.

Occup Health Saf. 2004 Mar;73(3):32-6, 38. No abstract available.

PMID:
15074135
37.

Cognitive Testing Battery: differences among groups with dementia, Huntington's disease, and controls.

Hyer L, Sohnle S, Miller MH, Hamer R.

Psychol Rep. 2003 Oct;93(2):497-504.

PMID:
14650681
38.

Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.

Jumbe N, Louie A, Leary R, Liu W, Deziel MR, Tam VH, Bachhawat R, Freeman C, Kahn JB, Bush K, Dudley MN, Miller MH, Drusano GL.

J Clin Invest. 2003 Jul;112(2):275-85.

39.
40.

Iris configuration in accommodation in pigment dispersion syndrome.

Balidis MO, Bunce C, Sandy CJ, Wormald RP, Miller MH.

Eye (Lond). 2002 Nov;16(6):694-700.

41.

Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection.

Louie A, Kaw P, Liu W, Jumbe N, Miller MH, Drusano GL.

Antimicrob Agents Chemother. 2001 Mar;45(3):845-51.

43.

Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice.

Wluka A, Buchbinder R, Mylvaganam A, Hall S, Harkness A, Lewis D, Littlejohn GO, Miller MH, Ryan PF.

J Rheumatol. 2000 Aug;27(8):1864-71.

PMID:
10955325
44.
46.

Differential attrition rates and active parental consent.

Esbensen FA, Miller MH, Taylor TJ, He N, Freng A.

Eval Rev. 1999 Jun;23(3):316-35.

PMID:
10538786
47.

Prevalence of leg wound complications after coronary artery bypass grafting: determination of risk factors.

Goldsborough MA, Miller MH, Gibson J, Creighton-Kelly S, Custer CA, Wallop JM, Greene PS.

Am J Crit Care. 1999 May;8(3):149-53.

PMID:
10228655
48.

Is stapedectomy ever ethical? An audiologist replies.

Miller MH.

Am J Otol. 1999 Jan;20(1):140-1. No abstract available.

PMID:
9918191
49.

Comparison of fluconazole pharmacokinetics in serum, aqueous humor, vitreous humor, and cerebrospinal fluid following a single dose and at steady state.

Mian UK, Mayers M, Garg Y, Liu QF, Newcomer G, Madu C, Liu W, Louie A, Miller MH.

J Ocul Pharmacol Ther. 1998 Oct;14(5):459-71.

PMID:
9811235
50.

Telehealth and OSHA.

Miller MH.

ASHA. 1998 Fall;40(4):57-8. No abstract available.

PMID:
9796124

Supplemental Content

Loading ...
Support Center